830 WINTER STREET, WALTHAM, MA
Q32 Bio Presents SIGNAL-AA Trial Results at EADV 2026
José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer
Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Q32 Bio Inc. Enters Underwriting Agreement for 6M Shares at $18.25 Each
Investor Presentation
Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata
Announces $55 Million Private Placement Financing
Reports First Quarter 2026 Financial Results and Provides Corporate Update
Q2
Q1
FY 2025
Q3
FY 2024
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Amended Statement of Changes in Beneficial Ownership
Submission Upload
Correspondence
Post-Effective Amendment to Registration Statement